Company Overview
Company Type: Public Company
Website: www.edesabiotech.com
Number of Employees: 16
Ticker: EDSA (NasdaqCM)
Year Founded: 2015


Business Description
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that is in Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
18.0
EBITDA
(13.0)
Total Enterprise Value
9.4
TEV/EBITDA
NM
EBIT
(13.3)
Cash & ST Invst.
8.8
P/Diluted EPS Before Extra
NM
Net Income
(13.0)
Total Debt
0.2
Price/Tang BV
2.3x
Capital Expenditure
0.0
Total Assets
12.9
Total Debt/EBITDA
NM




Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-05-2023


Estimates Snapshot (Current Fiscal Year End: Sep-30-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
(0.14)
-
(0.61)
(2.26)
(1.85)
Revenue (mm)
0.00
-
0.00
0.00
0.00

Forward Multiples (Current FY)

Price/Earnings
NM

Non-Periodic Estimates

Recommendation
Buy (1.50)
Target Price
11.40
Potential Upside
1,233.33%


Key Professionals
Name
Title
Nijhawan, Pardeep 
CEO, Company Secretary & Director
Brooks, Michael J.
President
Lemieux, Stephen L.
Chief Financial Officer

Key Board Members
Name
Title
Sistilli, Carlo 
Independent Chairman of the Board
Nijhawan, Pardeep 
CEO, Company Secretary & Director
Chypyha, Joan 
Director
Oakes, Frank R.
Director
MacDonald, Sean Arthur
Independent Director
Marshall, Patrick Jeffrey
Director
Olson, Charles V.
Director


Primary Industry Classification
Biotechnology


Primary Office Location
100 Spy Court | Markham, ON | L3R 5H6 | Canada
Phone: 289 800 9600   

Current and Pending Investors
Armistice Capital LLC, FirstFire Capital Management LLC, Francis Capital Management, LLC, Intracoastal Capital LLC, Lagom LLC, Lumira Ventures (Peter van der Velden), Pardeep Nijhawan Medicine Professional Corporation, Pharmascience Inc., Starlight Investment Holdings Limited, The Bigger Capital Fund, LP, The Digestive Health Clinic Inc., The New Nijhawan Family Trust 2015, Tomsat Investment & Trading Co., Inc, Velan Capital Partners LP, YJP International Limited, York-Cav Enterprises, Inc.

Prior Investors
Inveready Asset Management, S.G.E.I.C., S.A. (Sara Secall)

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.85
Market Cap (mm)
18.0
Open
 0.85
Shares Out. (mm)
21.1
Previous Close
 0.85
Float %
66.8%
Change on Day
(0.01)
Shares Sold Short (mm)
0.3
Change % on Day
(0.8)%
Dividend Yield %
-
Day High/Low
 0.88/ 0.83
Diluted EPS Excl. Extra Items
(0.63)
52 wk High/Low
 3.84/ 0.70
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0042
Avg 3M Dly Vlm (mm)
0.07
Beta 5Y
0.82


 
Delayed Quote** | Last Updated on Oct-06-2023 11:58 AM (GMT-5)


Index Membership
S&P Completion Index (CI);S&P TMI Index;S&P Completion Index (CI) Health Care (US Dollar);S&P TMI Health Care


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Stellar Biotechnologies, Inc.
As of June 7, 2019, Stellar Biotechnologies, Inc. was acquired by Edesa Biotech Inc., in a reverse merger transaction. Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.

United States and Canada
Biotechnology
0.00
9.00
0.00
Edesa Biotech Research, Inc.
Edesa Biotech Research, Inc. develops and commercializes pharmaceutical products for therapeutic, prophylactic, and diagnostic uses. The company was founded in 2015 and is based in Markham, Canada. Edesa Biotech Research, Inc. operates as a subsidiary of Edesa Biotech, Inc.

United States and Canada
Pharmaceuticals
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-24-2023
-
Shelf Registration
Target
Edesa Biotech, Inc. (NasdaqCM:EDSA)


1.27
Mar-27-2023
-
Public Offering
Target
Edesa Biotech, Inc. (NasdaqCM:EDSA)


8.37
Dec-16-2022
Dec-23-2022
Shelf Registration
Target
Edesa Biotech, Inc. (NasdaqCM:EDSA)

Velan Capital Partners LP
10.07
Nov-02-2022
Nov-02-2022
Private Placement
Target
Edesa Biotech, Inc. (NasdaqCM:EDSA)
Pardeep Nijhawan Medicine Professional Corporation,The New Nijhawan Family Trust 2015

2.22
Aug-5-2022
-
Shelf Registration
Target
Edesa Biotech, Inc. (NasdaqCM:EDSA)


150.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-28-2023
Product-Related Announcements
Edesa Biotech, Inc. Publishes Phase 2 Substudy Results of ARDS Drug Candidate
Sep-11-2023
Company Conference Presentations
Edesa Biotech, Inc. Presents at H.C. Wainwright 25th Annual Global Investment Conference, Sep-11-2023
Aug-10-2023
Company Conference Presentations
Edesa Biotech, Inc. Presents at Canaccord Genuity 43rd Annual Growth Conference, Aug-10-2023 12:00 PM
Jun-28-2023
Product-Related Announcements
Edesa Biotech's Ards Drug Inhibits Inflammation from Influenza and Other Pathogens
Jun-27-2023
Executive Changes - CFO
Edesa Biotech Appoints Biotech Deal Veteran to CFO, Effective July 15, 2023

M&A Advisors
Fasken Martineau DuMoulin LLP, Stubbs Alderton & Markiles LLP


Advisors
Most Recent Auditor
MNP LLP
M&A Advisors
Fasken Martineau DuMoulin LLP, Stubbs Alderton & Markiles LLP
Public Offering Advisors
Brookline Capital Markets, LLC, Fasken Martineau DuMoulin LLP, H.C. Wainwright & Co., LLC, Lowenstein Sandler LLP, MNP LLP, Stubbs Alderton & Markiles LLP


Most Recent Auditor
Meyers Norris Penny LLP - MNP LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 03:46 AM
EDSA
Edesa Biotech Inc 2023_10_05
Reports
14
ValuEngine, Inc.

Oct 02, 2023 03:59 AM
EDSA
ValuEngine Rating and Forecast Report for EDSA
Reports
11
GlobalData

Sep 21, 2023 05:45 AM
EDSA
Edesa Biotech Inc (EDSA.NASD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
72
GlobalData

Sep 21, 2023 05:43 AM
EDSA
Edesa Biotech Inc (EDSA.NASD) - Medical Equipment - Deals and Alliances Profile
Reports
37
MarketLine

Sep 20, 2023 06:01 AM
EDSA
Edesa Biotech Inc
Reports
46
GlobalData

Sep 15, 2023 10:00 AM
EDSA
Edesa Biotech Inc (EDSA.NASD) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
70
GlobalData

Sep 13, 2023 11:17 PM
EDSA
Edesa Biotech Inc (EDSA.NASD) - Financial Analysis Review
Reports
291
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Sep 13, 2023 06:00 PM
EDSA
Rating Update for Edesa Biotech Inc
EPS Estimates*
3
S&P Global Compustat

Sep 07, 2023 03:35 AM
EDSA
Edesa Biotech Inc 2023_09_07
Reports
14
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Aug 16, 2023 06:00 PM
EDSA
Is Edesa Biotech Inc for Long-Term Investors?
Ratings Change*
12


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Nijhawan FRCPC, M.D., Pardeep 

2,951,726

13.99

2.6

Aug-04-2023


Lumira Ventures

1,775,408

8.42

1.5

Jan-12-2023


Velan Capital Partners LP

1,281,615

6.08

1.1

Jun-30-2023


CM Management, LLC

375,000

1.78

0.3

Jun-30-2023


1968160 Ontario Inc.

371,727

1.76

0.3

Aug-04-2023


The New Nijhawan Family Trust 2015

228,262

1.08

0.2

Aug-04-2023


The Digestive Health Clinic Inc.

224,094

1.06

0.2

Aug-04-2023


Brooks M.B.A., Ph.D., Michael J.

123,680

0.59

0.1

Aug-04-2023


The Vanguard Group, Inc.

110,882

0.53

0.1

Jun-30-2023


Geode Capital Management, LLC

86,696

0.41

0.1

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Brooks M.B.A., Ph.D., Michael J.
123,680
93,200
Canadian Imperial Bank of Commerce, Asset Management Arm
54,626
54,626
CM Management, LLC
375,000
50,000
Lemieux BA, CA, CPA, MMPA, Stephen L.
17,400
17,400
Wells Fargo & Company, Private Banking and Investment Banking Arm
117
7

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Lynwood Capital Management Inc.
0
(287,500)
Renaissance Technologies LLC
0
(17,502)
Two Sigma Investments, LP
11,571
(15,137)
Johnson Ph.D., Lorin K.
0
(12,786)
Simplicity Solutions, LLC
0
(10,000)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
EB01 (Future), EB02 (Future), EB05 (Future), EB06 (Future), EB07 (Future)


Upcoming Events
Date/Time
Type
Oct-31-2023
Company Conference Presentations
Oct-31-2023
Conferences
Nov-06-2023
Company Conference Presentations
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-28-2023
-
Edesa Biotech, Inc. (NasdaqCM:EDSA)
SEDAR
News Releases
44 KB
Aug-10-2023
-
Edesa Biotech, Inc. (NasdaqCM:EDSA)
SEDAR
News Releases
78 KB
Aug-10-2023
-
Edesa Biotech, Inc. (NasdaqCM:EDSA)
SEDAR
News Releases
106 KB
Aug-09-2023
-
Edesa Biotech, Inc. (NasdaqCM:EDSA)
SEDAR
Documents Affecting the Rights of Security Holders
93 KB
Aug-09-2023
-
Edesa Biotech, Inc. (NasdaqCM:EDSA)
SEDAR
Documents Affecting the Rights of Security Holders
93 KB
Aug-09-2023
Jun-30-2023
Edesa Biotech, Inc. (NasdaqCM:EDSA)
SEDAR
Interim Financial Statements
169 KB
Aug-09-2023
Jun-30-2023
Edesa Biotech, Inc. (NasdaqCM:EDSA)
SEC
10-Q
4 MB
Aug-09-2023
Aug-09-2023
Edesa Biotech, Inc. (NasdaqCM:EDSA)
SEC
8-K (2.02, 9.01)
267 KB
Jul-26-2023
-
Edesa Biotech, Inc. (NasdaqCM:EDSA)
SEDAR
News Releases
78 KB
Jun-28-2023
-
Edesa Biotech, Inc. (NasdaqCM:EDSA)
SEDAR
News Releases
82 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Lemieux BA, CA, CPA, MMPA, Stephen L. (Chief Financial Officer)
Aug-04-2023
Common shares
17,400
-
Other Acquisition
New
Form 4
Nijhawan FRCPC, M.D., Pardeep  (CEO, Company Secretary & Director)
Aug-04-2023
Common shares
99,300
-
Other Acquisition
3.36
Form 4
Brooks M.B.A., Ph.D., Michael J. (President)
Aug-04-2023
Common shares
93,200
-
Other Acquisition
305.77
Form 4
Lumira Ventures
Jan-11-2023 - Jan-12-2023
Common shares
131,908
458,769
Open Market Acquisition
8.03
Exchange Announcement
-
Jan-11-2023
Common shares
93,364
326,200
Open Market Acquisition
-
Exchange Announcement
-
Jan-12-2023
Common shares
27,379
93,737
Open Market Acquisition
-
Exchange Announcement
-
Jan-11-2023
Common shares
8,633
30,162
Open Market Acquisition
-
Exchange Announcement
-
Jan-12-2023
Common shares
2,532
8,669
Open Market Acquisition
-
Exchange Announcement
Lumira Ventures
Jan-09-2023 - Jan-10-2023
Common shares
(297,474)
(1,077,422)
Open Market Disposition
(14.35)
Multiple
-
Jan-10-2023
Common shares
(12,895)
(46,468)
Open Market Disposition
-
Exchange Announcement
-
Jan-09-2023
Common shares
(12,284)
(44,728)
Open Market Disposition
-
Exchange Announcement
-
Jan-10-2023
Common shares
(139,450)
(502,515)
Open Market Disposition
-
Exchange Announcement
-
Jan-09-2023
Common shares
(132,845)
(483,711)
Open Market Disposition
-
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Sistilli, Carlo 
Independent Chairman of the Board
289 800 9600
-

Nijhawan, Pardeep 
CEO, Company Secretary & Director
289 800 9600
-

Chypyha, Joan 
Director
289 800 9600
-

Oakes, Frank R.
Director
289 800 9600
-
foakes@stellarbiotech.com
MacDonald, Sean Arthur
Independent Director
289 800 9600
-

Marshall, Patrick Jeffrey
Director
289 800 9600
-

Olson, Charles V.
Director
289 800 9600
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Nijhawan, Pardeep 
CEO, Company Secretary & Director
289 800 9600
-

Brooks, Michael J.
President
289 800 9600
-

Lemieux, Stephen L.
Chief Financial Officer
289 800 9600
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
